Emergence of drug-resistant viruses, high cost and adverse side-effects associated with the standard therapy against hepatitis C virus (HCV) infection demonstrate the need for development of well tolerated and effective antivirals. We identified and chemically characterised the dehydrorotenoid boeravinone H, isolated from the herb Boerhavia diffusa, as a new inhibitor of HCV entry. The compound significantly inhibits the binding and entry of hepatitis C-like particles (HCV-LPs) in hepatoma cells in vitro with no apparent cytotoxicity. Boeravinone H inhibits the initial phase of HCV entry probably by acting directly on the viral particle. Importantly, the compound prevents HCV entry and infection in cell culture (ex vivo). Thus, boeravinone H is a potential antiviral agent for the prevention and control of HCV infection.
Hepatitis C virus (HCV) is a major cause of chronic viral hepatitis which leads to liver fibrosis and cirrhosis with high risk of developing hepatocellular carcinoma [1] . It is estimated that~160 million people worldwide are chronically infected with HCV [2] . Substantial morbidity and mortality caused by HCV intends a significant threat to human health. Till date there is no protective vaccine for the prevention of HCV infection, and therapeutic options to combat chronic hepatitis are still limited. The current standard therapy based on the administration of pegylated interferon either alone or in combination with ribavirin [3] results in a low sustained virological response (SVR). The recently approved direct-acting antivirals (DAAs) that inhibit HCV NS3/4A protease or NS5B polymerase activity when included in the treatment regimen have dramatically increased the SVR and improved treatment options [4] [5] [6] [7] [8] . However, treatment with DAAs is fraught with limitations associated with severe sideeffects and emergence of resistant viruses [9] [10] [11] [12] [13] [14] [15] . The high expense of the current therapy restrain their use in developing countries where infection is most prevalent [16] , thereby demonstrating the need to develop new, well tolerated and more efficient antivirals with low production cost. The replication step of the viral life cycle is mostly targeted by the majority of DAAs. Recent findings have suggested that combination of entry inhibitors with DAAs exhibit a synergistic effect Abbreviations DAA, direct-acting antiviral; EDTA, ethylenediaminetetraacetic acid; FBS, fetal bovine serum; FT-IR, Fourier transform infra-red; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HCV, hepatitis C virus; HCV-LPs, hepatitis C virus-like particles; HPLC, high-performance liquid chromatography; IC 50 , half maximal inhibitory concentration; JFH, Japanese fulminant hepatitis; MS, mass spectrometry; MTT, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]; NMR, nuclear magnetic resonance; PBS, Phosphate buffered saline; PCR, polymerase chain reaction; VLPs, virus-like particles.
in the treatment of HCV [17] . Moreover, after liver transplantation, reinfection of the graft with HCV occurs in patients [18] which could be prevented by efficient HCV entry inhibitors.
Phytochemicals have been considered conducive for prevention of several viral infections and are found to be promising antiviral agents. The recent global trend is inclined towards the development of new drugs from natural sources as an alternative to the conventional synthetic drugs. Till date several plant extracts have been screened for their antiviral effect against various viral infections including hepatitis C [19] [20] [21] [22] .
The Indian flora has immense importance in traditional medicines and represents a vast resource of potential therapeutic compounds. We aimed to explore and evaluate extracts from Indian medicinal plants with reported hepatoprotective effects, for screening HCV entry inhibitors. In the Indian subcontinent, the predominant HCV genotype is 3a, and therefore hepatitis C virus-like particle (HCV-LP) comprising of core-E1-E2 derived from genotype 3a was used in our study. HCV-LPs represent a model system for the study of viral attachment and entry [23, 24] . Of the many plants studied, the extract of the herb Boerhavia diffusa showed antiviral activity as measured by inhibition of binding of HCV-LPs to human hepatoma cells. Upon isolation and subsequent structural characterisation, the active principal was revealed to be a dehydrorotenoid, namely, boeravinone H. Importantly, the compound also inhibited HCV (Japanese fulminant hepatitis [JFH]1 virion) entry and infection in the cell culture system (ex vivo). To our knowledge, this is the first report on the anti-HCV activity of boeravinone H that may be explored for use as effective therapeutics.
Materials and methods

Cell culture
Human hepatocellular carcinoma cells Huh7 and Huh7.5 (gift from C. M. Rice, Apath LLC, St. Louis, MO, USA) [25] were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (FBS) and glutamax (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA) at 37°C in a humidified incubator under 5% CO 2 . The insect cells, Sf21 were maintained in TC100 medium (Sigma-Aldrich) supplemented with 10% FBS, at 28°C.
Purification and labelling of HCV-LPs
The recombinant baculovirus consisting of core-E1-E2 of HCV genotype 3a (Acc. No. core: GU172376 and E1E2: GU172375) and genotype 1b (Acc. No. AJ238799) were generated as described previously [26] . Sf21 cells were infected with recombinant baculovirus at a moi of 5-10 and cells were harvested 72 h post infection. Cell pellets were washed with phosphate buffered saline (PBS; 50 mM phosphate buffer, pH 7.2, containing 150 mM NaCl) and were resuspended in lysis buffer (50 mM Tris, 50 mM NaCl, 0.5 mM ethylenediaminetetraacetic acid, 1 mM PMSF, 0.1% NP40 and 0.25% protease inhibitors) and lysed using a tissue homogenizer. Next, the lysate was centrifuged at 1500 g for 15 min at 4°C. The supernatant was layered over a 30% sucrose cushion and centrifuged at 111 132 g in SW41 rotor (Beckman and Coulter, Brea, MN, USA). The pellet was resuspended in 20 mM Tris, pH 7.0 containing 150 mM NaCl and applied on a 20-60% continuous sucrose gradient for ultracentrifugation. Ultracentrifugation was performed for 22 h at 111 132 g at 4°C and fractions (1 mL) were collected. Fractions containing HCV-LPs (of genotype 3a and 1b) were diluted with PBS and then centrifuged for 2 h at 111 132 g. The pellet was then dissolved in PBS and stored at À80°C for future use.
As described earlier, HCV-LPs were labelled with Alexa-488 dye (Invitrogen, ThermoFisher Scientific) [27, 28] . Briefly, 10 lL of 10 mgÁmL À1 Alexa dye was added to 2 mgÁmL À1 of virus-like particles (VLPs) dissolved in 1 mL of 0.1 M sodium bicarbonate buffer (pH 9) and incubated for 2 h at room temperature (RT) with constant stirring. The labelled VLPs were separated from the free dye by desalting on a Sephadex G-25 desalting column.
Preparation of plant extract
The plants used in the study were identified and collected from their natural habitat. The leaves of Centella asiatica, Andrographis paniculata, Ficus benghalensis and Ocimum sanctum were collected from the campus of Indian Institute of Science, Bangalore, and specimens were stored in the laboratory. Leaves were dried in the shade and pulverised using a grinder. 50 g of each sample was extracted with 100 mL of methanol under constant shaking for 24 h at RT and filtered to remove insoluble debris. The extracts were concentrated under reduced pressure using Rotary Evaporator (IKA, Staufen, Germany). The Slurry was then allowed to air-dry and stored at À20°C. The methanolic extracts of B. diffusa and Picrorhiza kurroa were received as kind gifts from Natural Remedies, Bangalore, India.
Purification and identification of the active compound
For the isolation of the active component, the extract of B. diffusa was subjected to thin layer chromatography (TLC) using the selected solvent system of chloroform: methanol: acetic acid in the ratio of 8 
Preparation of test samples
Stocks of the different crude extracts and purified compounds boeravinone H and (-)-epigallocatechin-3-gallate (EGCG from Sigma-Aldrich) were prepared in Dimethyl sulfoxide (DMSO from Sigma-Aldrich) and diluted in DMEM (serum free) for the in vitro and cell culture studies.
Cytotoxicity assay
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was performed using standard protocol [29] . Huh7 cells were plated in 96-well plates at a density of 5 9 10 3 cells per well in DMEM for 24 h at 37°C. After 24 h, varying concentrations of extracts (final concentration ranging from 30 lgÁmL À1 to 1 mgÁmL À1 ) or the compound boeravinone H (final concentration ranging from 15.6 lM to 2 mM) were added. The plates were incubated for 24 h in the presence of the extracts or for 24 and 48 h in the presence of the purified compound; 20 lL of MTT (SigmaAldrich) solution was added to each well and incubated for 4 h at 37°C. The MTT solution was aspirated and the formazan crystals formed were extracted in 100 lL of DMSO in each well. The colour intensity was measured at 550 nm using an ELISA plate reader.
Inhibition of HCV-LP binding to Huh7 cells by extracts/purified compounds
The 
Time of addition experiment
Boeravinone H was added before, during or after addition of labelled HCV-LPs to Huh7 cells. In case of pretreatment of cells, boeravinone H was added to Huh7 cells and incubated for 1 h. After subsequent washes, labelled HCV-LPs was added and further incubated for 2 h and cell-bound fluorescence was determined by flow cytometry as described above. In case of postattachment, labelled HCV-LPs were incubated with Huh7 cells for 1 h and then boeravinone H was added and incubated further for 2 h. After subsequent washes, cell-bound fluorescence was assessed as demonstrated previously. DMSO and EGCG were used as negative and positive controls, respectively.
In case of pretreatment of HCV-LPs, boeravinone H was preincubated with the labelled VLPs for 1 h and then the complex was allowed to bind to Huh7 cells for another 2 h. The rest of the procedure is same as described above.
Virus neutralisation assay in cell culture (ex vivo)
The cell culture-derived infectious HCV-JFH1 viral particles were generated as described previously [25, 31] . Boeravinone H and EGCG (positive control) were tested for their ability to inhibit HCV entry by measurement of reduction in the HCV RNA levels. The purified compounds were preincubated with the JFH1 viral particles for 1 h at 37°C. The virus-compound complex was then added to Huh7.5 cells and incubated for 4 h at 37°C followed by subsequent washes. The infectivity was analysed by real-time polymerase chain reaction (PCR) 3 days postinfection. For the detection of HCV negative strand, total RNA was isolated and reverse transcribed with HCV IRES 5 0 forward primer and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 3 0 reverse primer. Using SYBR green PCR master mix (Thermo Scientific), the resulting cDNA was quantified. Using the ABI ViiA7 real-time PCR system, the cDNA was amplified for HCV IRES and GAPDH (internal control). The set of primers used are as follows: labelled HCV-LPs in the presence or absence of boeravinone H at 4°C for 1 h followed by incubation for 2 h at 37°C to examine the effect of the compound on HCV-LP internalisation. Unbound HCV-LPs were removed by washing with PBS. The cells were fixed with formaldehyde, and the nucleus was stained with Hoechst (5 lgÁmL
À1
) and mounted on slides using fluoromount G. The images were acquired using an Olympus 1X81 motorised inverted fluorescence microscope (Olympus Corporation, Tokyo, Japan) and analysed with manufacturer provided CELLSENS DIMENSION software.
Confocal microscopy
JFH1 virus was preincubated with the purified compounds briefly for 30 min and infected Huh7.5 cells for 4 h at 37˚C followed by subsequent washes with PBS and changed to complete medium. Seventy-two hours post infection, cells were fixed with paraformaldehyde, permeabilised with 0.1% Triton-X-100 and blocked with 3% BSA in PBS. Next cells were incubated with combinations of the labgenerated anti-E2 protein mAbs A8A11 and C10E8 [32] , for 90 min, washed with PBS and then incubated with Alexa-488 conjugated anti-mouse-IgG antibody (Invitrogen, ThermoFisher Scientific). The nuclei were stained with DAPI (Sigma-Aldrich). The images were acquired in a confocal microscope (Zeiss LSM 710, Carl Zeiss Microscopy, Oberkochen, Germany) and analysed in ZEN software (Carl Zeiss Microscopy).
Statistical analysis
GRAPHPAD PRISM5 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for the analysis of data. To determine statistical significance, unpaired t-test was performed for each dataset.
Results
Evaluation of toxicity of extracts
Based on collected information, seven Indian medicinal plants with known hepatoprotective effect were short listed (Table 1 ). To assess the cytotoxic effect of the methanolic extracts of plants against host cells, MTT assay was performed. Huh7 cells were treated with varying concentration of the extracts and cell viability was determined. Extracts of plants such as Centella sp., Picrorhiza sp. and Boerhavia sp. did not exhibit any cytotoxicity, whereas extracts of Andrographis sp., Ficus sp., Ocimum sp. and Hibiscus sp. (Fig. S1 ) were toxic at higher concentrations. 
Effect of extracts on HCV-LP binding to hepatoma cells
The inhibitory activity of the extracts on the binding of HCV to Huh7 cells was determined using HCV-like particles (HCV-LPs). The plant extracts (200 lgÁmL À1 ) were incubated with Huh7 cells along with HCV-LPs and inhibition of binding was determined by flow cytometry.
Results obtained suggest that only extract of the root of B. diffusa significantly inhibited (~63%; P < 0.0001) HCV-LP binding to host cells (Fig. 1) . Therefore, the extract of B. diffusa was selected for further studies.
Isolation of the active component with antiviral activity
The crude extract of B. diffusa was fractionated by TLC. The extract separated into 16 components by analytical preparative TLC-guided fractionation in the selected solvent system (chloroform : methanol : acetic acid). These components were further evaluated for inhibition of HCV-LP binding to hepatoma cells. Huh7 cells were incubated with HCV-LPs in the presence of each of these components at a concentration of 20 lgÁmL À1 or EGCG, a known HCV entry inhibitor [19, 33] , at the same concentration and decrease in cellular binding of VLP was measured by flow cytometric analysis. Among all the components tested, only fraction 8 (R f value 0.45) showed significant inhibition (~72%; P < 0.0001; Fig. 2 ).
Identification of the bioactive compound with antiviral activity
The C NMR spectra of the compound identified the dehydrorotenoid, boeravinone H (Fig. 3A,B) . The IR spectrum further supported the structure by confirming the presence of ether (1267 cm À1 ), alcohol (3300-3400 cm
À1
) and ketone (1733 cm À1 ) functional groups (Fig. S3) . Thus, our data indicate that the bioactive compound responsible for the anti-HCV property of B. diffusa is boeravinone H, with molecular formula of C 19 H 16 O 7 (Fig. 3C) .
Effect of boeravinone H on HCV-LP binding to host cells
Having purified and identified the compound as boeravinone H, the toxicity of the compound on Huh7 cells was determined by MTT assay. No toxicity was observed up to a concentration of 500 lM but moderate toxicity of~22% was observed at higher concentrations of 2 mM (Fig. 4A) . Next, to assess and confirm the antiviral activity of boeravinone H, the compound was incubated with Huh7 cells along with Alexa-488 labelled HCV-LPs and fluorescence was measured by flow cytometry. It was evident from the result that boeravinone H significantly inhibited HCV-LP binding to hepatoma cells in a dose-dependent manner (Fig. 4B,C) with the half maximal inhibitory concentration (IC 50 ) between 12.5 and 25 lM and the 90% inhibitory concentration was estimated to be close to~200 lM.
Boeravinone H inhibits HCV binding and entry in vitro
The HCV entry step is a complex process that involves virus cell binding, virus uptake and delivery into the cytoplasm. To identify the stage at which the inhibition by boeravinone H takes place, we performed time of addition experiment, where the compound was added before, during or after addition of labelled HCV-LPs to Huh7 cells. The result clearly demonstrates that only in the presence of boeravinone H there is a significant inhibition of HCV-LP binding to hepatoma cells (~80% and~90% at a concentration of 100 and 200 lM, respectively) (Fig. 5B) . Our data also suggest that there was no inhibition of binding when boeravinone H was added to cells prior to the addition of VLP (Fig. 5A) or at a postattachment step where VLPs were added to cells prior to the addition of the compound (Fig. 5C ). These results taken together suggest that boeravinone H acts at an early entry step which is most likely the attachment step.
Boeravinone H inhibits HCV entry and seems to have no effect if added as a pretreatment of cells suggesting that it acts on the viral particle. This observation was confirmed by experiments where boeravinone H was preincubated with labelled HCV-LPs at varying concentrations and then the complex was added to Huh7 cells and the cell-bound fluorescence was measured by flow cytometry. Result demonstrates that the inhibitory effect of boeravinone H was higher when HCV-LPs were preincubated with the compound (Fig. 5D) , suggesting that it acts directly on the viral particle thereby inhibiting the binding and entry of HCV-LP to the host cell surface. Moreover, fluorescence microscopy studies also confirmed that in the presence of the compound boeravinone H (at a concentration of 100 and 200 lM), there is a significant reduction of HCV-LP entry and internalisation in Huh7 cells (Fig. 6) .
In India, HCV genotype 3a is predominant, followed by HCV genotype 1b. We, therefore, also investigated the effect of boeravinone H on the binding of HCV-LPs (derived from genotype 1b) to Huh7 cells. Results suggest a significant inhibition of binding of HCV-LP 1b to hepatoma cells in a dose-dependent manner (Fig. S4) which was comparable to that of genotype 3a.
Inhibition of HCV entry and infection in the HCVcc system
To confirm the effect of boeravinone H on HCV entry, the cell culture system (HCVcc) was employed. The infectious JFH1 virus was preincubated with the compound followed by infection of Huh7.5 cells for 4 h at 37°C. After 3 days post infection, the HCV negative strand synthesis was measured by real-time PCR. Results obtained suggest a significant inhibition of virus infection as demonstrated by a drastic reduction (> 95%; P < 0.0002) in the intracellular HCV RNA level in cells infected with HCV in the presence of boeravinone H as compared with the another fraction of the extract taken as control (Fig. 7A) .
We went on to confirm the effect of boeravinone H on HCV binding to cells and entry as analysed by HCV envelope protein expression, by confocal microscopy. Results showed a significant reduction of virus infection in the presence of the purified compound as compared with another fraction of the extract taken as negative control (Fig. 7B ). DMSO and EGCG have been considered as solvent control and positive control, respectively.
Discussion
The new treatment regimen of HCV which includes DAAs is associated with severe side effects, high cost and poses risk for the development of resistance. Therefore, there is an urgent need for alternative therapies which would be safe, readily available to the vast majority of patients and affordable. For decades, plant-based remedies have been used traditionally for the treatment of various diseases. Phytochemicals isolated from plants are of immense importance and some have been found to have potential antiviral properties [22] . Natural products usually display characteristics of high chemical diversity compared with standard combinatorial chemistry. In comparison to conventional drugs, natural compounds are safe and well tolerated. A number of natural compounds have been isolated in recent years which possess potential anti-HCV activity. Many of these compounds are reported to interfere with different stages of the virus lifecycle [19] as observed in the case of silymarin, naringenin, proanthocyanidin, quercetin, EGCG, ladanein, curcumin and others [19, 33, [35] [36] [37] [38] .
We screened for entry inhibitors for HCV from natural sources using HCV-LPs comprising of core, E1 and E2 protein derived from genotype 3a, since it is the predominant genotype in India. Based on available literature on Indian traditional medicine, we explored and evaluated the effect of extracts from different medicinal plants that are known to exert hepato-protection. Among all the plant extracts tested, only the methanolic extract of the herb B. diffusa significantly inhibited (~63%) binding of HCV-LPs to hepatoma cells. Importantly, the extract of B. diffusa was observed to be nontoxic to human hepatoma (Huh7) cells. Boerhavia diffusa is a well-known medicinal plant in traditional Indian medicine. It has been classified as a 'rasayana' herb in Ayurveda [34] . The herb belongs to the family Nyctaginaceae and is widely studied for its therapeutic properties. In vitro and in vivo studies with the extract of the different parts of B. diffusa, especially the roots, have demonstrated activities like immunomodulation, hepatoprotection, diantifibrinolysis, anticancer, antidiabetic, anti-inflammatory, antimicrobial, antifungal and diuresis [34] . It is also reported to possess antioxidant activity [39] .
After detection of anti-HCV activity in the crude extract of the root of B. diffusa, we went ahead with the isolation and identification of the relevant bioactive compound. Identification and chemical characterisation of the compound was achieved by LC-ESI-MS, NMR and IR spectral analysis. The compound was confirmed to be a dehydrorotenoid and namely boeravinone H. Flow cytometric analysis revealed that boeravinone H significantly inhibited binding of Alexa-488 labelled HCV-LPs to Huh7 cells. The IC 50 dose was estimated to lie between 12.5 and 25 lM concentration and the IC 90 dose was~200 lM which is similar to the reported active concentration of other HCV inhibitors derived from natural sources [19] . Boeravinone H was observed to be nontoxic to hepatocytes up to 500 lM concentration even after 48 h of treatment, and only minimal toxicity (~22%) Fig. 6 . Boeravinone H inhibits HCV entry. Huh7 cells were incubated with labelled HCV-LPs alone or in the presence of boeravinone H for 1 h at 4°C followed by 2 h at 37°C. After washing, the cells were fixed and nuclei stained with Hoechst dye. Cells were mounted on slides and observed under Olympus inverted fluorescence microscope. Fig. 7 . Inhibition of HCV entry in cell culture mediated by boeravinone H. (A) JFH1 virus was incubated with boeravinone H (200 lM) for 1 h at 37°C before infecting Huh7.5 cells at 37°C for 4 h. Three days post infection, total cellular RNA was isolated. The HCV negative strand was measured using real-time PCR. Control denotes a TLC-separated fraction of the Boerhavia diffusa root that did not show inhibition in vitro and EGCG was taken as positive control. The relative HCV RNA level in the presence of boeravinone H compared to control is statistically significant (***P < 0.0002). (B) JFH1 virus was preincubated with boeravinone H (100 and 200 lM) followed by infection of Huh7.5 cells for 4 h at 37°C. Seventy-two hours post infection cells were fixed and probed with anti-E2 mAbs followed by incubation with Alexa-488 conjugated anti-mouse secondary antibody. The nuclei were stained with DAPI and images were acquired in a confocal microscope (LSM 710). Negative control denotes a TLC fraction that did not show inhibition in vitro. DMSO and EGCG have been considered as solvent and positive control, respectively.
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FEBS Letters 591 (2017) 1305-1317 ª 2017 Federation of European Biochemical Societies was observed at high concentration. The time of addition experiment and fluorescence microscopy studies demonstrate that boeravinone H acts at the early entry step, probably by inhibiting the attachment of the virus to the cell surface. Furthermore, our in vitro experiments also suggest that boeravinone H directly acts on the viral particle since inhibition in binding was observed only when the particles were preincubated with the compound but not the cells. More importantly, boeravinone H significantly inhibited (> 95%) HCV entry and infection in the HCVcc system (ex vivo) which is revealed by the significant reduction in the HCV negative strand synthesis in realtime PCR after 3 days post infection. Therefore, it is evident from our data that the compound boeravinone H inhibits HCV entry both in the HCV-LP and HCVcc system. Since the compound acts directly on the viral particle and inhibits HCV binding and entry both in vitro and ex vivo, it might be speculated that it interferes with the function of the envelope glycoproteins. Our results also imply that boeravinone H affects the binding and entry of HCV genotypes 3a, 2a and 1b into hepatoma cells to a comparable extent.
The entry step in the lifecycle of HCV is important for the initiation and spread of the infection; therefore, identification of entry inhibitors serves as an attractive approach for antiviral therapy [17] . In case of chronic HCV patients, entry inhibitors would prevent de novo infection thereby leading to viral clearance [36, 40] . Most of the drugs that are in the final stages of clinical studies target the replication stage of HCV. Nevertheless, in the scenario of liver transplantation where reinfection of donor allograft occurs in almost all cases [18] , identification of inhibitors with the ability to inhibit HCV entry in hepatocytes will be greatly beneficial. Moreover, a combination of drugs targeting different stages of the virus life cycle including viral entry would be a better approach to combat HCV infection and entry inhibitors given along with the DAAs would be expected to exhibit a synergistic effect. Moreover, the current therapy is unlikely to get replaced by natural compounds but can be supplemented by them since they are well tolerated and less expensive. Further investigation is required for the determination of bioavailability of the molecule.
In conclusion, the highlight of the study is the identification of a new HCV entry inhibitor, boeravinone H (a dehydrorotenoid) isolated from the herb B. diffusa that appears to be a promising antiviral for the management of HCV infection. To our knowledge, boeravinone H is the first dehydrorotenoid reported to exhibit anti-HCV activity.
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